1. 2540 Experience with radium-223 as a systemic treatment for patients (pts) with castration-resistant prostate cancer (CRPC) out of a clinical trial in Spain. (September 2015) Authors: Grande, E.; Pinto, A.; Dur´n, I.; López-Criado, P.; Su´rez, C.; Gonz´lez-Larriba, J.L.; S´nchez-Lorenzo, L.; Maroto, P.; L´inez, N.; Gonz´lez del Alba, A.; S´ez, M.I.; Alonso-Gordoa, T.; Pérez-Valderrama, B.; Puente, J.; Morales, R.; Esteban, E.; Manneh, R.; Benedetti, J.; Carles-Galcerán, J.; Ca... Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S488 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2902 GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation. (September 2015) Authors: Sepúlveda, J.M.; Vaz, M.A.; Gil, M.; Reynés, G.; Gallego, O.; Bolós, M.V.; Laýn, A. Hernádez; Sánchez-Gómez, P.; Martýnez, M.; Vicente, E.; Quindos, M.; Luque, R.; Ramos, A.; Ruano, Y.; Manneh, R.; Segura, P. Pérez; Benavides, M.; Balañá, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S585 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 8P Cdk4/6 inhibitor activity in metastatic bladder cancer cell lines is independently of RB1 status. (20th December 2016) Authors: Castellano, D.; Rubio, C.; López-Calderón, F.; Segovia, C.; Dueñas, M.; Martinez-Fernández, M.; Otero, I.; Manneh, R.; De Velasco, G.; Paramio, J. Journal: Annals of oncology Issue: Volume 27(2016:Sep.)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗